Azevan Pharmaceuticals, Inc.

Developing Next Generation for the treatment of Central Nervous Disorders

Stress, Mood, and Behavioral Disorders

Stress-Related Affective Illness: Major Depression and Anxiety Disorders affect over 35 million Americans each year. Many patients with major depression or anxiety disorders (e.g., PTSD) show elevated levels of vasopressin that decline as illness improves.

Women's Health and Pain: Primary Dysmenorrhea, Premenstrual Syndrome (PMS) and Premenstrual Dysphoric Dysmenorrhea (PMDD) are a constellation of menstrual-related disorders that adversely impact quality of life in women. Clinical reports show efficacy of vasopressin antagonists for the treatment of pain in dysmenorrhea.

Raynaud’s Disease, a vasospastic disorder defined by severe pain in the extremeties, is five times more prevalent in women and is associated with emotional stress.

Azevan Pharmaceuticals, Inc. is developing novel therapeutics for the treatment of disorders of stress, mood, and behavior. The Company leverages its expertise in behavioral neurobiology with its proprietary chemistry platform targeting G-protein coupled receptors (GPCRs) to create drug candidates. Azevan’s first series of clinical candidates selectively block the effects of arginine vasopressin (AVP), which is involved in the pathophysiology of various conditions including anxiety, depression, menstrual-related disorders (primary dysmenorrhea, premenstrual syndrome, and premenstrual dysphoric disorder), and Raynaud’s Disease.

Phase I trial for first clinical candidate, SRX251, completed in 2008
Phase I trial for second clinical candidate, SRX246, anticipatedin Q2 2009
Clinical candidates are orally active, GPCR-targeted, small molecules that cross the blood-brain barrier
Azevan’s library is based on proprietary azetidinone chemistry that can be manipulated to target additional high-value GPCRs
Venture-backed company founded and run by experienced chemists and neurobiologists